P/E ratio for Regulus Therapeutics (RGLS)

P/E ratio history for Regulus Therapeutics from 2012 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
GlaxoSmithKline GSK	11.5	-1,563.52%	🇬🇧 UK
Sanofi SNY	18.7	-2,471.35%	🇫🇷 France
Biogen BIIB	8.16	-1,137.40%	🇺🇸 USA
AstraZeneca AZN	38.3	-4,964.42%	🇬🇧 UK
Alnylam Pharmaceuticals ALNY	-56.7	7,105.76%	🇺🇸 USA
Sangamo Therapeutics SGMO	-0.6865	-12.76%	🇺🇸 USA
Bristol-Myers Squibb BMY	15.9	-2,119.96%	🇺🇸 USA
Dicerna Pharmaceuticals DRNA	N/A	N/A	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.